These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 22863920)

  • 21. Peculiarities of L: -DOPA treatment of Parkinson's disease.
    Kostrzewa RM; Nowak P; Kostrzewa JP; Kostrzewa RA; Brus R
    Amino Acids; 2005 Mar; 28(2):157-64. PubMed ID: 15750845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease.
    Oechsner M; Buhmann C; Strauss J; Stuerenburg HJ
    J Neural Transm (Vienna); 2002; 109(1):69-75. PubMed ID: 11793163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. β-asarone and levodopa coadministration increases striatal levels of dopamine and levodopa and improves behavioral competence in Parkinson's rat by enhancing dopa decarboxylase activity.
    Huang L; Deng M; Zhang S; Lu S; Gui X; Fang Y
    Biomed Pharmacother; 2017 Oct; 94():666-678. PubMed ID: 28787702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons.
    Atlas D
    CNS Neurosci Ther; 2016 Jun; 22(6):461-7. PubMed ID: 26861609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of 3-O-methyl on L-dopa-facilitated synthesis and efflux of dopamine from rat striatal slices.
    Chang WY; Webster RA
    Br J Pharmacol; 1995 Nov; 116(6):2637-40. PubMed ID: 8590982
    [TBL] [Abstract][Full Text] [Related]  

  • 26. L-dopa upregulates the expression and activities of methionine adenosyl transferase and catechol-O-methyltransferase.
    Zhao WQ; Latinwo L; Liu XX; Lee ES; Lamango N; Charlton CG
    Exp Neurol; 2001 Sep; 171(1):127-38. PubMed ID: 11520127
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Coadministration of β-asarone and levodopa increases dopamine in rat brain by accelerating transformation of levodopa: a different mechanism from Madopar.
    Huang L; Deng M; Zhang S; Fang Y; Li L
    Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):685-90. PubMed ID: 24910244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of two new inhibitors of catechol O-methylation on striatal dopamine metabolism: a microdialysis study in rats.
    Törnwall M; Kaakkola S; Tuomainen P; Kask A; Männistö PT
    Br J Pharmacol; 1994 May; 112(1):13-8. PubMed ID: 7518301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease.
    Ishihara A; Miyachi T; Nakamura T; Ohtsuki T; Kimura Y; Kihira K; Yamawaki T; Matsumoto M
    Hiroshima J Med Sci; 2011 Sep; 60(3):57-62. PubMed ID: 22053701
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of high single doses of levodopa and carbidopa on brain dopamine and its metabolites: modulation by selective inhibitors of monoamine oxidase and/or catechol-O-methyltransferase in the male rat.
    Männistö PT; Tuomainen P
    Naunyn Schmiedebergs Arch Pharmacol; 1991 Oct; 344(4):412-8. PubMed ID: 1766471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of the catechol-O-methyltransferase Val158Met polymorphism on the pharmacokinetics of L-dopa and its metabolite 3-O-methyldopa in combination with entacapone.
    Yamamoto J; Omura T; Kasamo S; Yamamoto S; Kawata M; Yonezawa A; Taruno Y; Endo H; Aizawa H; Sawamoto N; Matsubara K; Takahashi R; Tasaki Y
    J Neural Transm (Vienna); 2021 Jan; 128(1):27-36. PubMed ID: 33136226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 3-O-methyl-DOPA is not involved in the development of behavioral supersensitivity after repeated L-dopa administration in 6-OHDA lesioned rats.
    Bräutigam K; Sohr R; Morgenstern R
    Behav Brain Res; 1994 Jul; 63(1):41-5. PubMed ID: 7945976
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of a novel catechol-O-methyltransferase inhibitor, nitecapone, on the metabolism of L-dopa in healthy volunteers.
    Kaakkola S; Gordin A; Järvinen M; Wikberg T; Schultz E; Nissinen E; Pentikäinen PJ; Rita H
    Clin Neuropharmacol; 1990 Oct; 13(5):436-47. PubMed ID: 2272023
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 3-O-Methyldopa inhibits astrocyte-mediated dopaminergic neuroprotective effects of L-DOPA.
    Asanuma M; Miyazaki I
    BMC Neurosci; 2016 Jul; 17(1):52. PubMed ID: 27456338
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concentrations of tyrosine, L-dihydroxyphenylalanine, dopamine, and 3-O-methyldopa in the cerebrospinal fluid of Parkinson's disease.
    Tohgi H; Abe T; Takahashi S; Nozaki Y; Kikuchi T
    Neurosci Lett; 1991 Jun; 127(2):212-4. PubMed ID: 1908962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Catechol-O-methyltransferase and Parkinson's disease.
    Reches A; Fahn S
    Adv Neurol; 1984; 40():171-9. PubMed ID: 6695593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Favorable effect of catechol-O-methyltransferase inhibition by OR-462 in experimental models of Parkinson's disease.
    Lindén IB; Nissinen E; Etemadzadeh E; Kaakkola S; Männistö P; Pohto P
    J Pharmacol Exp Ther; 1988 Oct; 247(1):289-93. PubMed ID: 3171977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Catechol-O-methyltransferase inhibition protects against 3,4-dihydroxyphenylalanine (DOPA) toxicity in primary mesencephalic cultures: new insights into levodopa toxicity.
    Blessing H; Bareiss M; Zettlmeisl H; Schwarz J; Storch A
    Neurochem Int; 2003 Jan; 42(2):139-51. PubMed ID: 12421594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Binding of dopamine and 3-methoxytyramine as l-DOPA metabolites to human alpha(2)-adrenergic and dopaminergic receptors.
    Alachkar A; Brotchie JM; Jones OT
    Neurosci Res; 2010 Jul; 67(3):245-9. PubMed ID: 20302892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.